Vascular endothelial growth factor

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Retrieved on:

Tuesday, May 18, 2021

Branches of biology, Angiology, Medical specialties, Clinical medicine, Growth factors, Vascular endothelial growth factor, Angiogenesis, Checkpoint inhibitor, Bavituximab

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.

Key Points:

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.
This allows OncXerna to pair those patients with OncXerna\xe2\x80\x99s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
OncXerna\xe2\x80\x99s clinical trials currently combine bavituximab with KEYTRUDA\xc2\xae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors.

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Retrieved on:

Thursday, May 13, 2021

GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD.

Key Points:

GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD.
In a genetically-defined subset of AMD patients, GEM103 may circumvent dysfunctional CFH loss-of-function variants and slow the progression of their retinal disease.
In patients undergoing anti-VEGF treatment, GEM103 may help regulate the hyperactive amplification of the alternative pathway believed to lead to cell loss and macular atrophy.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy.

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

Retrieved on:

Wednesday, May 12, 2021

Branches of biology, Clinical medicine, Ophthalmology, Angiology, Vascular endothelial growth factor, Intravitreal administration, Macular degeneration, Angiogenesis, Retina, Angiogenesis inhibitor

The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.

Key Points:

The proliferation of abnormal blood vessels in the retina is stimulated by VEGF.
There are on average 200,000 new incidences of wet AMD per year in the United States alone.
The prevalence of DME is high, affecting approximately 1.1 million adults in the United States.\n4D-150 is designed as a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members to prevent angiogenesis for the treatment of wet AMD and DME.
No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\n'

Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021

Retrieved on:

Wednesday, May 12, 2021

Drugs, Branches of biology, Health care, Orphan drugs, Angiogenesis inhibitors, Bevacizumab, Vascular endothelial growth factor, Macular degeneration, Food and Drug Administration

With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision.

Key Points:

With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision.
If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets.
Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.
For more information, please visit www.outlooktherapeutics.com .\n'

China Aflibercept Market Report 2021: An Anti-VEGF Drug - Relevant Concepts, Sales 2018-2020, Major Manufacturers 2018-2020, Prices 2020-2021, & Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on:

Monday, May 10, 2021

Health, Pharmaceutical, Branches of biology, Life sciences, Countries, Breakthrough therapy, Angiogenesis inhibitors, Aflibercept, Sanofi, Regeneron Pharmaceuticals, Bayer, Vascular endothelial growth factor, Macular degeneration, Economy of China

b'The "Investigation Report on China\'s Aflibercept Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment.

Key Points:

b'The "Investigation Report on China\'s Aflibercept Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nAflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment.
Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Aflibercept, EYLEA was launched in China in 2018.
By 2020, Bayer AG is the only manufacturer in the Chinese Aflibercept market.\nAccording to this market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY 110 million in 2020.
Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.\n2 Sales of Aflibercept in China, 2018-2020\n2.3 Sales of Aflibercept by Dosage Form in China, 2018-2020\n3 Analysis of Major Aflibercept Manufacturers in China, 2018-2020\n4 Prices of Aflibercept for Different Manufacturers in China, 2020-2021\n5 Prospect of Chinese Aflibercept drug Market, 2021-2025\n'

Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Retrieved on:

Thursday, May 6, 2021

Angiology, Branches of biology, Medical specialties, Vascular endothelial growth factor, Angiogenesis, Endothelium, Angiogenesis inhibitor, Anti–vascular endothelial growth factor therapy

The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

Key Points:

The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.
Most approved therapeutics target vascular endothelial growth factor (VEGF), a pro-angiogenic factor with neurotrophic and neuroprotective effects.
However, approximately 50% of Patients do not respond to anti-VEGF/Corticosteroids therapies.\nOCU200 inhibited cell proliferation, cell invasion and tube formation by endothelial cells.
Arun Upadhyay, VP and Head of R&D, Ocugen Inc.\n'

Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021

Retrieved on:

Saturday, May 1, 2021

Branches of biology, Ophthalmology, Organ systems, Vascular endothelial growth factor, Macular degeneration, Angiology, Angiogenesis inhibitors, Conbercept

Patients in OPTIC are difficult-to-treat and had previously received frequent anti-vascular endothelial growth factor (VEGF) treatment.

Key Points:

Patients in OPTIC are difficult-to-treat and had previously received frequent anti-vascular endothelial growth factor (VEGF) treatment.
The primary endpoint of the trial is the safety and tolerability of ADVM-022 after a single IVT administration.
In patients with wet AMD, an aggressive form of AMD, abnormal blood vessels grow underneath and into the retina.
Such statements include but are not limited to statements regarding the potential for ADVM-022 in treating wet AMD and DME.

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Retrieved on:

Saturday, May 1, 2021

Branches of biology, Biology, Organ systems, Blindness, Diabetes, Diabetic retinopathy, Bcl-xL, Macular edema, Retinopathy, Senolytic, Vascular endothelial growth factor, Retina

Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectively promotes apoptosis of diseased senescent cells of the retina, thereby restoring healthy vasculature and improving retinal function \xe2\x80\x93 important distinctions from anti-VEGF treatments.

Key Points:

Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectively promotes apoptosis of diseased senescent cells of the retina, thereby restoring healthy vasculature and improving retinal function \xe2\x80\x93 important distinctions from anti-VEGF treatments.
\xe2\x80\x9cRetinal vascular diseases, namely diabetic retinopathy and macular edema, are primary causes of blindness in the United States, but current treatments are less than ideal.
Mike Sapieha will also participate in a panel discussion at ARVO 2021 focused on neglected pathways in vision loss.
In the study described, the novel senolytic candidate, UBX1325, selectively inhibits Bcl-xL, promoting apoptosis in oxygen induced retinopathy models but not normoxic controls.

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

Retrieved on:

Thursday, April 29, 2021

Branches of biology, Growth factors, Vascular endothelial growth factor, Angiology, Tyrosine kinase receptors, Signal transduction

As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.

Key Points:

As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.
The overall safety profile is similar to that of marketed single-target anti-VEGF drugs.
IBI302 was designed to provide more targeted treatment and interventions to the cause of nAMD by adding additional targets.
The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Retrieved on:

Sunday, April 11, 2021

At the time of data cutoff, 16 patients (64%) remained on study treatment.

Key Points:

At the time of data cutoff, 16 patients (64%) remained on study treatment.
The combination of sitravatinib and tislelizumab was generally well tolerated and showed promising antitumor activity among patients with advanced PROC, including those who were heavily pretreated.
Sitravatinib targets the VEGFR and TAM (TYRO3, AXL, MERTK) receptor families, which are implicated in orchestrating an immunosuppressive tumor microenvironment (TME).
We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA\xc2\xae (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.